Articles

O.2 AXL: A potential therapeutic target to eliminate cancer cells and improve chemotherapeutic responses in different hematological cancers

BJH - volume 11, issue Abstract Book BHS, february 2020

N. Vandewalle , P. Vlummens MD, N. De Beule , S. Faict , I. Oudaert , K. Maes , E. De Bruyne , E. Menu , K. Vanderkerken PhD, K. De Veirman

Read more

P1.04 Tumor-associated macrophages induce Multiple Myeloma cell survival and STAT3 activation

BJH - volume 7, issue Abstract Book BHS, january 2016

N. De Beule , K. De Veirman , K. Maes , E. De Bruyne , E. Menu , R. Schots MD, PhD, K. Vanderkerken PhD, E. Van Valckenborgh PhD

Read more

P1.01 Myeloid Derived Suppressor Cells induce Multiple Myeloma cell survival through AMPK activation

BJH - volume 6, issue Abstract Book BHS, january 2015

K. De Veirman , J. van Ginderachter , N. De Beule , S. Lub , A. Maes , E. De Bruyne , E. Menu , I. Van Riet PhD, K. Vanderkerken PhD, E. Van Valckenborgh PhD

Read more

P.34 Multiple Myeloma in the era of novel agents: a single center experience

BJH - 2013, issue BHS Abstractbook, january 2013

N. De Beule , K. Fostier MD, A. De Becker MD, C. Caron , F. Trullemans , R. Schots MD, PhD

Read more